Figure 2.

(A) Gemcitabine titration in KPC#5508 cells. Fitting of the data revealed an IC₅₀ of 100 nM +/− 15 nM. (B) RAGE inhibition increases gemcitabine cytotoxicity in KPC #5508 cells, in vitro. Cell viability of KPC #5508 cells was measured after 48 h of treatment with either media alone (Ctrl), 100 nM IgG 2A11, 100 nM gemcitabine, or 100 nM IgG 2A11 and 100 nM gemcitabine. (C) RAGE inhibition enhances the cytotoxicity of gemcitabine in vivo. Mice orthotopically implanted with KPC #5508 cells were treated with either non-immune IgGs (Ctrl IgGs), IgG 2A11, Ctrl IgGs and gemcitabine, or the combination of IgG 2A11 and gemcitabine. Pancreatic tumor weights were measured after 3 weeks of treatment. (D) RAGE inhibition protects against weight loss in gemcitabine-treated mice. The body weight of the mice was recorded at the end of the three weeks of treatment. * p < 0.05; ** p < 0.01; *** p < 0.001.